Khan Amal M, Alswat Khaled A
Resident, Family Medicine Residency Program, Ministry of Health, Taif, Saudi Arabia.
Department of Medicine, Taif University School of Medicine, Taif, Saudi Arabia.
Diabetes Spectr. 2019 Feb;32(1):30-35. doi: 10.2337/ds18-0015.
Insulin-treated patients demonstrate low adherence to insulin injections, which results in poor glycemic control. The i-Port Advance is a new advanced injection method. Our aim was to evaluate patient satisfaction, glycemic control, and adherence with this device.
This prospective study examined i-Port use in 55 insulin-treated patients. Baseline characteristics and Diabetes Treatment Satisfaction Questionnaire status (DTSQs) scores were collected at baseline and at the end of the follow-up period. All patients were trained to use the i-Port. Patients were divided into two groups: regular users of the i-Port, who used it for ≥3 months, and irregular users, who used it for <3 months. Local complications during use of the i-Port were recorded.
Of the 55 patients, 92.7% had type 1 diabetes, the mean age was 14.96 ± 8.95 years, and 92.7% used an insulin pen. The patients were divided into 27 regular users and 28 irregular users. Irregular users had a longer duration of diabetes ( = 0.901) at baseline compared to regular users, were less likely to report noncompliance with insulin usage ( = 0.338), were more likely to self-inject insulin ( = 0.038), and had a lower A1C ( = 0.056). There were no statistical differences between groups in mean DTSQs treatment satisfaction scores or mean glycemic control scores. At the end of the follow-up period, regular i-Port usage improved compliance with insulin usage ( = 0.028), reduced diabetes-related hospitalizations (P <0.001), and reduced the frequency of hypoglycemia ( = 0.184). Scarring at the i-Port site was the most common complication.
Regular i-Port usage improved compliance and decreased hospitalizations and hypoglycemic episodes, with a nonsignificant 0.73% reduction in A1C.
接受胰岛素治疗的患者对胰岛素注射的依从性较低，这导致血糖控制不佳。i-Port Advance是一种新的先进注射方法。我们的目的是评估患者对该设备的满意度、血糖控制情况及依从性。
这项前瞻性研究对55例接受胰岛素治疗的患者使用i-Port的情况进行了检查。在基线和随访期结束时收集基线特征和糖尿病治疗满意度问卷（DTSQs）评分。所有患者均接受了使用i-Port的培训。患者被分为两组：i-Port的常规使用者（使用时间≥3个月）和非常规使用者（使用时间<3个月）。记录使用i-Port期间的局部并发症。
55例患者中，92.7%患有1型糖尿病，平均年龄为14.96±8.95岁，92.7%使用胰岛素笔。患者被分为27名常规使用者和28名非常规使用者。与常规使用者相比，非常规使用者在基线时糖尿病病程更长（P = 0.901），报告胰岛素使用不依从的可能性更小（P = 0.338），自我注射胰岛素的可能性更大（P = 0.038），糖化血红蛋白（A1C）更低（P = 0.056）。两组在DTSQs治疗满意度评分均值或血糖控制评分均值方面无统计学差异。在随访期结束时，i-Port的常规使用提高了胰岛素使用的依从性（P = 0.028），减少了与糖尿病相关的住院次数（P<0.001），并降低了低血糖发生频率（P = 0.184）。i-Port部位的瘢痕形成是最常见的并发症。
i-Port的常规使用提高了依从性，减少了住院次数和低血糖发作，糖化血红蛋白降低了0.73%，差异无统计学意义。
